Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.

Slides:



Advertisements
Similar presentations
Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006.
Advertisements

Challenges to Pediatric Antiretroviral Treatment Elaine Abrams, David Hoos MTCT-Plus.
Rational Drug Use Supported by USAID Prescribing, Dispensing, Counseling and Adherence in ART Programs.
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
Tuberculosis in Children: Prevention Module 10C - March 2010.
Acute Retroviral Syndrome
The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Recent Advances in Antiretroviral Therapy Hail M. Al-Abdely, MD Consultant, Infectious Diseases.
MONITORING SYSTEM FOR THE ANTIRETROVIRAL THERAPY IN BRAZIL: LESSONS LEARNED AND FUTURE DIRECTIONS Marco Vitória, MD Brazilian STD/AIDS Programme - MOH.
Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.
KITSO AIDS Training Program
Changing Therapy Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents published October 2006 AETC NRC Slide Set.
Principles of HIV Therapy Simple is Better! Adeel A. Butt, MD Assistant Professor of Medicine and Infectious Diseases University of Pittsburgh Director,
Initiating Antiretroviral Therapy in Treatment-Naive Patients Charles B. Hicks, MD Associate Professor of Medicine, Division of Infectious Diseases and.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
Accomplishments Year 1 Encouraged HIV testing counseling with referrals to Phidisa 1 Education of Nursing Staff on Pediatric Wards Lectures to Medical.
Treatment of AIDS “Antiretroviral therapy & vaccines”
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.
PEDIATRIC HIV UPDATE NAZHA ABUGHALI, MD 5/31/02 Dr. Nazha Abughali is Assistant Professor of Pediatrics Case Western Reserve University Head of Pediatrics.
Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
Dr. Abdulkarim Alhethail
Issues to Consider in HIV Resistance Testing Jason Tokumoto, MD National HIV/AIDS Clinicians’ Consultation Center.
HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.
November 2004 Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.
Presented by: Siti Rohaizah bt Othman. Arv DRUGS AVAILABLE IN UMMC Combivir (Lamivudine + Zidovudine) Stocrin (Efavirenz 600mg) Kaletra (Lopinavir 200mg.
Combination Antiretroviral Therapy for HIV Infection by Ormrat Kampeerawipakorn.
ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.
2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.
HIV Treatment in Saskatchewan Kurt E. Williams MD FRCPC 2012/Feb/9 Saskatoon.
Introduction to ARV therapy
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Nurses SOAR! Training Curricula Series For More Information and Inquiries:
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
Update in HIV/AIDS New millennium, New challenge 王永衛 醫師 台北榮民總醫院感染科主治醫師.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Module IV: Paediatric ART Treatment. An Introduction to Antiretroviral Therapy Key questions: What are ARVs? Why do we give ARVs to HIV infected children.
Indications for Initiation of ARV Therapy in Children Age >1 Year Clinical Category CD4 + Cell Percentage Plasma HIV RNA Copy Number Recommendation AIDS.
Antiretroviral Therapy DHHS Guidelines. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents.
HIV INFECTION D - preventive Medicine. HIV INFECTION LEARNING OBJECTIVES  Describe the pathophysiology of HIV infection.  Describe the principal mechanisms.
TO EVALUATE EARLY ANTIVIRAL RESPONSE AND SAFETY OF A DUAL BOOSTED PROTEASE INHIBITORS REGIMEN INCLUDING LOPINAVIR/r (LPV) PLUS AMPRENAVIR (AMP) OR FORTOVASE.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HIV & AIDS BY DR. MOHAMMED ARIF HEAD OF THE VIROLOGY UNIT ASSOCIATE PROFESSOR & CONSULTANT VIROLOGIST.
HIV-1 dynamics Perelson et.al. Science 271:1582 (1996) Infected CD4 + lymphocytes Uninfected, activated CD4 + lymphocytes HIV-1 t 1/ days t 1/2.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere February 2006.
HIV DISEASE IN PREGNANCY
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.
HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Date of download: 6/3/2016 From: Report of the NIH Panel To Define Principles of Therapy of HIV Infection* Ann Intern Med. 1998;128(12_Part_2):
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
What’s New in the Perinatal Guidelines
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
PHARMACOTHERAPY III PHCY 510
Presentation transcript:

Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS Society

Guidelines for the use of antiretroviral agents in HIV infections Significant progress in the field of antiretroviral therapy over the past year. New drugs approved for clinical use and new insights gained in many aspect of therapy. An update of the first “Guidelines for the use of antiretroviral agents in HIV infections in Taiwan” established in March 11, 2001, and organized a meeting on November 24, 2001.

Guidelines for the use of antiretroviral agents in HIV infections The new guidelines: more conservative in the initiation of treatment in asymptomatic patients, and offered an option for treatment in patients with CD4 + T cells >350/mm 3

Guidelines for the use of antiretroviral agents in HIV infections Other important issues not included in this guidelines: the side effects, drug resistance, patients compliance, prevention of opportunistic infections, Immunotherapy, and vaccine.

Guidelines for the use of antiretroviral agents in HIV- infected patients A. General consideration 1.When to start (1) Acute HIV infection: treatment should be offered. (2) Symptomatic: treatment should be offered. (3) Asymptomatic:

Adult: Treatment should be offered: CD4 + T cells <350/mm 3, or HIV RNA >30,000 copies/ml (bDNA), or HIV RNA >55,000copies/ml (RT-PCR). Treatment may be deferred: CD4 + T cells >350/mm 3, or HIV RNA <30,000 copies/ml (bDNA), or HIV RNA <55,000copies/ml (RT-PCR).

Pediatrics: Treatment should be offered to all newly diagnosed infected children, if universal early treatment not feasible, treatment should be offered if there is evidence of immune suppression as followings: CD4 + T cells Ages No./mm 3 % 1-5 yrs <1000 <25% 6-12 yrs <500 <25%

2.When to change (1)Virologic failure: a. A reduction in plasma HIV RNA of less than 0.5 to 0.7 log 10 4 weeks following initiation of therapy; or less than 1 log 10 by week 8. b. Failure to suppress plasma HIV RNA to undetectable levels within 4 -6 months after initiation of therapy.

c. Repeated detection of virus in plasma after initial suppression to undetectable level, suggesting the development of resistance. d. Any reproducible significant increase, defined as 3-fold or greater, from the nadir of plasma HIV RNA not attributable to intercurrent infection, vaccination, or test methodology. (2) Toxicity (3) Intolerance

B. Recommended regimens a 1.Acute HIV infection Drug of choice Alternative A B A B Indinavir Combivir b Abacavir AZT+3TC Saquinavir d4T+3TC AZT+ddI Ritonavir ddI+3TC AZT+ddc Nelfinavir d4T+ddI Efavirenz Nevirapine Saquinavir+Ritonavir Indinavir+Ritonavir Kaletra c

2.Asymptomatic HIV infection Drug of choice Alternative A B A B Indinavir Combivir b Abacavir AZT+3TC Saquinavir d4T+3TC AZT+ddI Ritonavir ddI+3TC AZT+ddc Nelfinavir d4T+ddI Efavirenz Nevirapine Saquinavir+Ritonavir Indinavir+Ritonavir Kaletra c

3.Advanced HIV infection Drug of choice Alternative A B A B Indinavir Combivir b Abacavir AZT+3TC Saquinavir d4T+3TC Nevirapine AZT+ddI Ritonavir ddI+3TC AZT+ddc Nelfinavir d4T+ddI Efavirenz Nevirapine Saquinavir+Ritonavir Indinavir+Ritonavir Kaletra c

4.HIV-infected pediatric patients d Drug of choice Alternative A B A B Ritonavir e AZT g +3TC e Abacavir e AZT g +ddC e Nelfinavir f AZT g +ddI f Nevirapine f d4T e +3TC e d4T e +ddI f

5.HIV infection in pregnant women Drug of choice Alternative A B A B Nevirapine Combivir Nelfinavir AZT+3TC Saquinavir AZT+ddI Indinavir d4T+3TC Ritonavir

6.Prophylaxis after occupational exposure h Drug of choice Alternative A B A B Indinavir Combivir Nelfinavir AZT+3TC Saquinavir d4T+3TC

Abbreviations: d4T : Stavudine 3TC: Lamivudine AZT: Zidovudine ddI: didanosine ddC: Zalcitabine a Antiretroviral drug regimens are comprised of one choice from column A and B. b Combivir: AZT+3TC. c Kaletra: lopinavir/ritonavir.

d All regimens used for adults are also recommended for pediatrics. e Oral solution formulation available. f Powder formulation for suspension available. g Syrup formulation available. h The previous treatment regimens of source patient should be taken into consideration; the duration of treatment is 4 weeks; the risk group should be considered, if contact with body fluid except blood, dual therapy is recommended.

Developed by the Panel on Clinical Practices for Treatment of HIV infection convened by the Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1 infected in Adults and Adolescents October 29, 2004

It is emphasized that concepts relevant to HIV management evolve rapidly. The panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the AIDSinfo Web site. (

Antiretroviral therapy is recommended for all patients with history of an AIDS-defining illness or severe symptoms of HIV infection regardless of CD4 + T cells count. Antiretroviral therapy is also recommended for asymptomatic patients with CD4 + T cells < 200/mm 3. When to treat: Indication for antiretroviral therapy Panel ’ s Recommendations

Asymptomatic patients with CD4 + T cells counts of /mm 3 should be offered treatment. Asymptomatic patients with CD4 + T cells counts of >350/mm 3 and plasma HIV RNA>100,000 copies/ml, most experienced clinicians defer therapy but some clinician consider initiating treatment.

Therapy should be deferred for patients with CD4 + T cells counts of >350/mm 3 and plasma HIV RNA<100,000 copies/ml.